Novel macrocyclic HCV NS3 protease inhibitors derived from α-amino cyclic boronates.

A novel series of P2-P4 macrocyclic HCV NS3/4A protease inhibitors with α-amino cyclic boronates as warheads at the P1 site was designed and synthesized. When compared to their linear analogs, these macrocyclic inhibitors exhibited a remarkable improvement in cell-based replicon activities, with compounds 9a and 9e reaching sub-micromolar potency in replicon assay. The SAR around α-amino cyclic boronates clearly established the influence of ring size, chirality and of the substitution pattern. Furthermore, X-ray structure of the co-crystal of inhibitor 9a and NS3 protease revealed that Ser-139 in the enzyme active site traps boron in the warhead region of 9a, thus establishing its mode of action.

[1]  C. Kettner,et al.  Synthesis of boronic acid analogues of alpha-amino acids by introducing side chains as electrophiles. , 2001, The Journal of organic chemistry.

[2]  V. Madison,et al.  P2-P4 macrocyclic inhibitors of hepatitis C virus NS3-4A serine protease. , 2006, Bioorganic & medicinal chemistry letters.

[3]  A. Prongay,et al.  Potent inhibitors of HCV-NS3 protease derived from boronic acids. , 2009, Bioorganic & medicinal chemistry letters.

[4]  B. Wang,et al.  Biological and Medicinal Applications of Boronic Acids , 2006 .

[5]  F. G. Njoroge,et al.  Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection. , 2008, Accounts of chemical research.

[6]  M. Chevallier,et al.  Clinical consequences of hepatitis C virus infection , 2003, Reviews in medical virology.

[7]  Paul Bamborough,et al.  Pyrrolidine-5,5-trans-lactams. 4. Incorporation of a P3/P4 urea leads to potent intracellular inhibitors of hepatitis C virus NS3/4A protease. , 2003, Organic letters.

[8]  Ann D. Kwong,et al.  VX-950, a Novel Hepatitis C Virus (HCV) NS3-4A Protease Inhibitor, Exhibits Potent Antiviral Activities in HCV Replicon Cells , 2006, Antimicrobial Agents and Chemotherapy.

[9]  C. Decicco,et al.  Design and synthesis of potent, non-peptide inhibitors of HCV NS3 protease. , 2003, Bioorganic & medicinal chemistry letters.

[10]  Dylan P. Hartley,et al.  Preclinical Characteristics of the Hepatitis C Virus NS3/4A Protease Inhibitor ITMN-191 (R7227) , 2008, Antimicrobial Agents and Chemotherapy.

[11]  Weiying Yang,et al.  Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: , 2006, Journal of medicinal chemistry.

[12]  Elizabeth Hamelink,et al.  Structure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350. , 2008, Bioorganic & medicinal chemistry letters.

[13]  J. Silver,et al.  Replication of Subgenomic Hepatitis C Virus Rnas in a Hepatoma Cell Line , 1999 .

[14]  M. Katharine Holloway,et al.  Molecular modeling based approach to potent P2-P4 macrocyclic inhibitors of hepatitis C NS3/4A protease. , 2008, Journal of the American Chemical Society.

[15]  M. Rudd,et al.  Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitor. , 2010, Journal of medicinal chemistry.

[16]  Brian L. Pearlman,et al.  Hepatitis C treatment update. , 2004, The American journal of medicine.

[17]  Z. Ni,et al.  Progress and development of small molecule HCV antivirals. , 2004, Current opinion in drug discovery & development.

[18]  K. Lindsay.  Therapy of hepatitis C: Overview , 1997, Hepatology.

[19]  A. Kwong,et al.  Preclinical Profile of VX-950, a Potent, Selective, and Orally Bioavailable Inhibitor of Hepatitis C Virus NS3-4A Serine Protease , 2006, Antimicrobial Agents and Chemotherapy.

[20]  P. Wei,et al.  Synthesis and antiviral activity of HCV NS3/4A peptidomimetic boronic acid inhibitors. , 2009, Bioorganic & medicinal chemistry letters.

[21]  Z. Ni,et al.  Synthesis and evaluation of novel alpha-amino cyclic boronates as inhibitors of HCV NS3 protease. , 2010, Bioorganic & medicinal chemistry letters.

[22]  J. I. Hernando,et al.  Inhibitors of hepatitis C virus NS3/4A: alpha-ketoamide based macrocyclic inhibitors. , 2009, Bioorganic & medicinal chemistry letters.

[23]  Martin Poirier,et al.  Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061. , 2004, Journal of medicinal chemistry.

[24]  C. Decicco,et al.  P1 Phenethyl peptide boronic acid inhibitors of HCV NS3 protease. , 2002, Bioorganic & medicinal chemistry letters.

[25]  John A Thomson,et al.  Hepatitis C virus NS3-4A protease inhibitors: countering viral subversion in vitro and showing promise in the clinic. , 2006, Current opinion in drug discovery & development.